Eli Lilly and Company has emerged as in the production of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant capacity to improve glycemic control and reduce cardiovascular risks. The sophisticated synthesis of tirzepatide utilizes a series of carefully controlle